Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Obesity and Type II Endometrial Cancer

Risk factors and survival outcomes

Obesity is highly prevalent in type II endometrial cancer (EC) patients, although there were no differences in outcomes as defined by BMI groups in an analysis of 154 type II EC cases. Patients were categorized into cohorts by BMI: normal, overweight, obese class I, and obese class IIIII and median follow-up was 41 months. Researchers found:

• Median progression-free survival (PFS) was 45.4, 36.0, 35.3, and 42.0 months and overall survival (OS) was 54.7, 44.7, 44.8 and 49.7 months, among the respective groups.

• There was no association between BMI and PFS, OS, or time to recurrence.

• There were no differences among the increasing BMI groups compared to normal weight women for the risk of death.

Citation: Billingsley CC, Cansino C, O’Malley DM, et al. Survival outcomes of obese patients in type II endometrial cancer: defining the prognostic impact of increasing BMI. [Published online ahead of print January 19, 2016]. Gynecol Oncol. doi: 10.1016/j.ygyno.2016.01.020.